Outcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon

Muhieddine Seoud; Iman Jaafar; Rayan Ghanem; Christiane Soubhieh; Abdallah Adra; Anwar Nassar; Ali Khalil

doi:10.1155/2022/7342061

Outcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon

Obstet Gynecol Int. 2022 Oct 12:2022:7342061. doi: 10.1155/2022/7342061. eCollection 2022.

Authors

Muhieddine Seoud¹, Iman Jaafar¹, Rayan Ghanem¹, Christiane Soubhieh¹, Abdallah Adra¹, Anwar Nassar¹, Ali Khalil¹

Affiliation

¹ American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.

Abstract

Objectives: The study aims to report on the feasibility and associated adverse events of HPV-Vaccination (HPVV) in a private clinic setting in Lebanon and, when available, the results of subsequent cervical cancer screening.

Methods: Opportunistic HPV vaccination is offered at the Women's Health Center of the AUBMC. We retrospectively reviewed the patients' demographic data, the incidence of adverse events, and their cytological screening.

Results: A cohort of healthy women (n = 1013) aged 26.2 years (12-54 years) were opportunistically vaccinated with one of two HPV vaccines; 845 (83.4%) received the quadrivalent vaccine (Q4V), and 151 (14.1%) received the bivalent vaccine (B2V). The majority (75.8%) received three doses while 16% received two doses. Out of these women, 26.3% (267) became sexually active postvaccination (NS2), whereas 17% (174) were sexually active prior to vaccination (SA) and the rest 57% (572) reported no sexual activity (NS1). Among the SA group, 26% (46/147) presented with abnormal cytology at time of vaccination. As for the NS2 women, 5% (14/267) had subsequently abnormal screening within 37 (12-103) months following vaccination.

Conclusions: In this observational study, we report the successful introduction of HPVV with negligible adverse events. The incidence of abnormal cervical cytology was low among our patients.